Vincent Levy
Overview
Explore the profile of Vincent Levy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1770
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
TP53 Mutations Detected by NGS Are a Major Clinical Risk Factor for Stratifying Mantle Cell Lymphoma
Lazarian G, Chemali L, Bensalah M, Zindel C, Lefebvre V, Thieblemont C, et al.
Am J Hematol
. 2025 Mar;
PMID: 40047370
No abstract available.
2.
Nault J, Boubaya M, Wartski M, Dohan A, Pol S, Pop G, et al.
Lancet Gastroenterol Hepatol
. 2025 Feb;
10(4):306-314.
PMID: 39987937
Background: The role of PET-CT with [F]fluorodeoxyglucose ([F]FDG) and [F]fluorocholine ([F]FCH) in staging hepatocellular carcinoma and treatment decisions has, to our knowledge, never been prospectively assessed. Methods: We conducted a...
3.
Nault J, Sritharan N, Verset G, Borbath I, Lequoy M, Allaire M, et al.
JHEP Rep
. 2025 Jan;
6(11):101192.
PMID: 39741695
Background & Aims: We aimed to explore patient expectations regarding their treatments and prognosis in comparison to physicians' assessments in patients with advanced hepatocellular carcinoma (HCC) receiving systemic treatments. Methods:...
4.
Choquet S, Marchal C, Deygas F, Deslandes M, Macher N, de Pouvourville G, et al.
Ann Hematol
. 2024 Jul;
103(8):2969-2981.
PMID: 38965145
Background: Ibrutinib is a Bruton's tyrosine kinase inhibitor indicated for the first-line treatment and relapse of chronic lymphocytic leukaemia (CLL), Waldenström's macroglobulinemia (WM) and mantle cell lymphoma (MCL). This study...
5.
Driouich J, Cochin M, Lingas G, Luciani L, Baronti C, Bernadin O, et al.
Biomed Pharmacother
. 2024 Jun;
177:116988.
PMID: 38897157
Therapeutic monoclonal antibodies have been successful in protecting vulnerable populations against SARS-CoV-2. However, their effectiveness has been hampered by the emergence of new variants. To adapt the therapeutic landscape, health...
6.
Boumendil L, Chevret S, Levy V, Biard L
Stat Med
. 2024 Jun;
43(18):3364-3382.
PMID: 38844988
Adaptive randomized clinical trials are of major interest when dealing with a time-to-event outcome in a prolonged observation window. No consensus exists either to define stopping boundaries or to combine...
7.
Hussein A, Levy V, Chevret S
Contemp Clin Trials
. 2024 Mar;
141:107506.
PMID: 38508234
Background: Since the 1950s, randomized clinical trials (RCTs) have served as the gold standard for confirming the benefits of a new drug. Accordingly, phase 3 trials, the last steps in...
8.
Mihoub I, Rharass T, Ouriemmi S, Oudar A, Aubard L, Gratio V, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139452
In the microenvironment, cell interactions are established between different cell types to regulate their migration, survival and activation. β-Catenin is a multifunctional protein that stabilizes cell-cell interactions and regulates cell...
9.
Boumendil L, Fontaine M, Levy V, Pacchiardi K, Itzykson R, Biard L
Biom J
. 2023 Nov;
66(1):e2200332.
PMID: 37984849
Drug combinations have been of increasing interest in recent years for the treatment of complex diseases such as cancer, as they could reduce the risk of drug resistance. Moreover, in...
10.
Sidali S, Sritharan N, Campani C, Gregory J, Durand F, Ganne-Carrie N, et al.
JHEP Rep
. 2023 Jul;
5(7):100755.
PMID: 37425214
Background & Aims: The fragility index (FI), i.e., theminimum number of best survivors reassigned to the control group required to revert the statistically significant result of a clinical trial to...